Clifton O. Bingham III, MD

Clifton O. Bingham III, MD
New York University School of Medicine, and NYU-Hospital for Joint Diseases, New York

Correspondence: Clifton O. Bingham III, MD, Assistant Professor of Medicine, NYU School of Medicine, Director, Ambulatory Clinical Research Center, NYU-Hospital for Joint Diseases, 301 E. 17th Street, Room 1410, New York, NY 10003; e-mail: clifton.bingham@med.nyu.edu

The author has indicated that he has been an investigator for Novartis and has served as a speaker and/or consultant for Merck, Pharmacia, and Pfizer.

Clifton O. Bingham III, MD
New York University School of Medicine, and NYU-Hospital for Joint Diseases, New York

Correspondence: Clifton O. Bingham III, MD, Assistant Professor of Medicine, NYU School of Medicine, Director, Ambulatory Clinical Research Center, NYU-Hospital for Joint Diseases, 301 E. 17th Street, Room 1410, New York, NY 10003; e-mail: clifton.bingham@med.nyu.edu

The author has indicated that he has been an investigator for Novartis and has served as a speaker and/or consultant for Merck, Pharmacia, and Pfizer.

Clifton O. Bingham III, MD
New York University School of Medicine, and NYU-Hospital for Joint Diseases, New York

Correspondence: Clifton O. Bingham III, MD, Assistant Professor of Medicine, NYU School of Medicine, Director, Ambulatory Clinical Research Center, NYU-Hospital for Joint Diseases, 301 E. 17th Street, Room 1410, New York, NY 10003; e-mail: clifton.bingham@med.nyu.edu

The author has indicated that he has been an investigator for Novartis and has served as a speaker and/or consultant for Merck, Pharmacia, and Pfizer.